Ferretti Stefano, Bossard Nadine, Binder-Fouchard Florence, Faivre Jean, Bordoni Andrea, Biavati Patrizia, Frassoldati Antonio
aDepartment of Public Health, Area Vasta Emilia Centrale Cancer Registry, Ferrara Local Health Unit bDepartment of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara cDepartment of Public Health, Area Vasta Emilia Centrale Cancer Registry, Bologna Local Health Unit, Bologna dClinical Oncology Unit, Department of Specialty Medicine, University Hospital Ferrara, Ferrara, Italy eDepartment of Biostatistics, University Hospital of Lyon fUniversity of Lyon, Lyon gUniversity of Lyon 1 hCNRS, UMR 5558,Biometry and Evolutionary Biology Laboratory (LBBE), BioMaths-Health Department iFrench Network of Cancer Registries (Francim), Toulouse jBas-Rhin Cancer Registry, Department of Epidemiology and Public Health, EA 3430, Faculty of Medicine, University of Strasbourg kDepartment of Public Health, University Hospital of Strasbourg, Strasbourg lRegistre Bourguignon des Cancers Digestifs, CHU de Dijon; INSERM U 866; University of Burgundy, Dijon, France mRegistro Tumori del Canton Ticino, Istituto cantonale di patologia, Locarno, Switzerland.
Eur J Cancer Prev. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S56-S62. doi: 10.1097/CEJ.0000000000000298.
Liver cancer represents a major clinical challenge. The aim of the SUDCAN collaborative study was to compare the net survival from liver cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain and Switzerland) and provide trends in net survival and dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Results are reported from 1992 to 2004 in France, Italy, Spain and Switzerland and from 2000 to 2004 in Belgium and Portugal. These trend analyses were carried out using a flexible excess-rate modeling strategy. There were little differences between the six countries in the 5-year age-standardized net survival (2000-2004): it ranged from 13% (France and Portugal) to 16% (Belgium). An increase in the net age-standardized survival was observed in all countries between 1992 and 2004, both at 1 year and at 5 years (the highest in Spain, the lowest in France). Generally, patients aged 60 years showed the highest increase. There was a progressive decrease in EMR over the 5-year- period following diagnosis. The study confirmed the poor prognosis of liver cancer. Innovative treatments might improve the prognosis as well as preventive screening of cirrhotic patients with good liver function. Efforts are also needed to improve registration practices.
肝癌是一项重大的临床挑战。SUDCAN合作研究的目的是比较六个欧洲拉丁国家(比利时、法国、意大利、葡萄牙、西班牙和瑞士)肝癌患者的净生存率,并提供确诊后长达5年的净生存率趋势以及超额死亡率(EMR)动态变化情况。数据取自EUROCARE - 5数据库。首先,使用波哈尔 - 佩尔梅估计量研究了2000 - 2004年期间的净生存率。对于趋势分析,研究时间段因国家而异。法国、意大利、西班牙和瑞士报告的结果涵盖1992年至2004年,比利时和葡萄牙报告的结果涵盖2000年至2004年。这些趋势分析采用了灵活的超额率建模策略。六个国家在5年年龄标准化净生存率(2000 - 2004年)方面差异不大:范围从13%(法国和葡萄牙)到16%(比利时)。1992年至2004年期间,所有国家在1年和5年时的年龄标准化净生存率均有所上升(西班牙上升幅度最大,法国最小)。总体而言,60岁患者的上升幅度最大。确诊后的5年期间,超额死亡率呈逐渐下降趋势。该研究证实了肝癌的预后较差。创新治疗方法可能会改善预后,同时也应对肝功能良好的肝硬化患者进行预防性筛查。还需要努力改进登记工作。